Objectives Assessment of patient-reported outcomes (PROs) in oncology is of critical
importance because it provides unique information that may also predict clinical outcomes …

In public health context, oncology is associated with severe negative impact on patients and
on their relatives' quality of life. Over the last decades, survival has remained at 50 …

Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …

Background In the CARD study, cabazitaxel significantly improved radiographic progression-
free survival and overall survival versus abiraterone or enzalutamide in patients with …

Purpose Understanding how patients and families experience, respond to, and cope with
the financial burden associated with cancer could assist in identifying future research …

Introduction: The efficacy of systemic first-line treatments in older adults with unresectable
hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and …

PURPOSE In the phase III KEYNOTE-181 study (NCT02564263) of patients with advanced
esophageal cancer (EC), pembrolizumab monotherapy prolonged overall survival versus …

Objective Lung cancer remains the number one cause of cancer-related mortality worldwide,
but less known is that lung cancer patients are among the most psychologically disabled of …

Background Atezolizumab, an immune checkpoint inhibitor, in combination with
chemotherapy (chemoimmunotherapy) has become a first-line treatment option for …

Background By eliminating the requirement for participants to make frequent visits to
research sites, mobile phone applications (“apps”) may help to decentralize clinical trials …